![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Drugmakers Push Back Against Exclusion Criteria for Rare Disease Trial
Drugmakers Push Back Against Exclusion Criteria for Rare Disease Trial
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
April 15, 2019
Two drug companies are pushing back against proposed FDA guidance that would require drug sponsors to hold pre-trials to determine whether patients with a nasty form of esophageal swelling could benefit from an alternate therapy.
Eosinophilic esophagitis is a rare disease of the immune system that can cause vomiting, difficulty swallowing, persistent heartburn and food getting struck in a patient’s esophagus. In February, the FDA published draft guidance that, among other things, would require drugmakers to screen out patients who would respond to proton pump inhibitor (PPI) therapy by holding a two-month trial of an “adequate dose” of PPI.
In public comments, both AstraZeneca and Adare Pharmaceuticals asked the agency to reconsider that recommendation.
Upcoming Events
-
21Oct